Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB Therapeutics

Drug Profile

Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB Therapeutics

Alternative Names: Glutathione-pegylated liposomal therapeutics - Sihuan/to-BBB

Latest Information Update: 03 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group; to-BBB technologies
  • Developer BBB Therapeutics; Sihuan Pharmaceutical Holdings Group
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 12 Feb 2014 Profile released, added ADMN.
  • 11 Dec 2013 Early research in CNS disorders in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top